AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold

Group 1 - The company reported Q4 revenues of $14.89 billion, representing a 25$2 billion, up 79% compared to the previous year [1] - Earnings per share (EPS) reached $0.97, reflecting a 71% increase year-on-year [1] Group 2 - The investment group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts and buy/sell ratings [1] - The group offers detailed product sales forecasts and integrated financial statements for major pharmaceutical companies [1] - The lead consultant, Edmund Ingham, has extensive experience in biotech and healthcare, having compiled reports on over 1,000 companies [1]